'Modest support' for PFS as OS surrogate in HER2-positive metastatic breast cancer

[News]

Progression-free survival only moderately correlates with overall survival at the individual and trial level in patients with HER2-positive metastatic breast cancer treated with HER2-targeted agents, say researchers.

More... (http://www.news-medical.net/news/20160323/Modest-support-for-PFS-as-OS-surrogate-in-HER2-positive-metastatic-breast-cancer.aspx)